Overall survival (OS) in BRCA -mutated breast cancer improved significantly with the addition of olaparib (Lynparza) to ...

Combination treatment with a PARP inhibitor and an anti-angiogenic agent did not improve PFS when compared to chemotherapy or a PARP inhibitor alone.

PARP inhibitors are FDA-approved for treatment of BRCA-altered ovarian, breast, prostate, and pancreatic cancers. Uterine sarcomas have high rates of somatic mutations in homologous recombination ...

The Business Research Company's Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Innovative Treatments Boost Poly(ADP ...

Treating patients with a drug before surgery greatly reduced the chances of the cancer coming back, a small trial found.

A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers, ...

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving ...

Mohammad Mahmoud, MD, MS, reviews important updates in metastatic prostate cancer presented at AUA 2025, including promising ...